Advocates call on Facebook to control vaccine misinformation; Democratic lawmakers to investigate government’s role in developing remdesivir; Pfizer CEO criticizes Trump drug price orders.
Five things for pharma marketers to know: Tuesday, July 28, 2020
Experts stress importance of education about coronavirus vaccines; Vaccine alliance says $40 should be maximum cost of vaccine; Moderna begins phase 3 trial of its vaccine.
Five things for pharma marketers to know: Monday, July 27, 2020
Opioid labels must include information about naloxone; Three of four Americans support mask requirements; Submit a cover design for the MM&M Hall of Femme issue.
U.S. sets benchmark for future COVID-19 vaccine prices; Researchers study wearables’ ability to detect COVID-19; Hims & Hers expands further into mental health care.
Publicis Groupe’s Sadoun: Nothing would make me happier than to prove agency doom-mongers ‘wrong’
Ninety percent of patients said the price Gilead is charging for remdesivir is not affordable, and nearly three-quarters said that the next COVID-19 treatment or vaccine should cost no more than $999.
Five things for pharma marketers to know: Thursday, July 23, 2020
Hospitals begin sharing COVID-19 data with HHS; U.S. to pay $2b for Pfizer, BioNTech coronavirus vaccine; California surpasses New York state coronavirus cases.
Teens with cystic fibrosis share social distancing tips in campaign from Area 23